Sponsors (2)
The bill significantly boosts and speeds SBIR/STTR funding for promising firms and tightens IP/national‑security protections, but does so at the cost of concentrating funds, adding new commercialization and compliance constraints (especially related to foreign ties), and imposing administrative burdens that may disadvantage some small firms and strain agencies.
Small businesses and researchers gain materially larger and faster non-dilutive R&D support: SBIR set‑asides rise (to 3.45%) and STTR (to 0.20%), high‑impact Phase II awards can be up to $30M (over longer periods), agencies must speed certain award decisions (90 days), and NIH/DOD may use more direct‑to‑Phase II funding—helping promising firms move R&D toward commercialization faster.
Awardees and federal programs get stronger IP and national‑security protections: new limits on foreign transfers, required agency due diligence and IG/intel coordination, and GAO study/annual reporting improve protection of federally funded technologies and oversight of foreign‑risk exposure.
Applicants and administrators face clearer statutory rules and reduced ambiguity: incorporations of SBIR/STTR definitions, clarified open‑topic announcements, editorial fixes, committee name updates, and a severability clause should lower disputes, reduce inconsistent interpretations, and preserve program stability.
Taxpayers, other R&D programs, and many researchers may see reduced funding diversity because larger set‑asides and the ability to concentrate up to $30M in Phase II awards can redirect agency funds toward fewer firms and away from other research priorities.
Small firms and investors face new commercialization and financing constraints: broad foreign‑tie denial grounds, 5–10 year prohibitions on foreign transfers, and investor disclosure/due‑diligence rules could bar otherwise‑eligible firms, limit foreign partnerships/sales, and deter venture financing.
Smaller and resource‑constrained firms may be disadvantaged by submission caps and open‑topic limits that favor incumbents able to concentrate resources on fewer, polished proposals rather than volume‑based application strategies.
Based on analysis of 14 sections of legislative text.
Increases SBIR/STTR set-asides, creates a $30M strategic Phase II track, caps cumulative awards, adds a Phase 1A pilot, tightens foreign-risk screening, and changes proposal and reporting rules.
Introduced July 25, 2025 by Roger Williams · Last progress July 25, 2025
Raises the minimum SBIR and STTR set-aside percentages for federal agencies starting in fiscal year 2026, creates a new “strategic breakthrough” funding track that can award much larger Phase II grants, caps how much a single small business can receive across Phase I and II awards, and adds new pilot, proposal, security, and reporting rules to the SBIR/STTR programs. It expands open-topic solicitations and a Phase 1A pilot to help new firms apply, tightens rules on foreign affiliations and national-security screening, limits how many proposals a firm can submit, and requires new data and reporting fields for federal procurement systems. The bill changes award sizes, eligibility, and oversight: bigger set-asides and a small proportion of funds dedicated to large strategic awards aim to speed high-cost technology development, while caps, proposal limits, and stricter foreign-risk rules limit concentration of funding and add security checks. Agencies and applicants will face new procedural, disclosure, and reporting requirements and must update contracting and data systems to track the new award categories.